L‑Lactate dehydrogenase B may be a predictive marker for sensitivity to anti‑EGFR monoclonal antibodies in colorectal cancer cell lines
Authors:
- 26 February 2019
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (5) , 4710-4716
Abstract
Recently, proteins derived from cancer cells have been widely investigated as biomarkers for predicting the efficacy of chemotherapy. In this study, to identify a sensitive biomarker for the efficacy of anti‑epidermal growth factor receptor monoclonal antibodies (anti‑EGFR mAbs), proteins derived from 6 colorectal cancer (CRC) cell lines with different sensitivities to cetuximab, an anti‑EGFR mAb, were analyzed. Cytoplasmic and membrane proteins extracted from each CRC cell line were digested using trypsin and analyzed comprehensively using mass spectrometry. As a result, 148 and 146 peaks from cytoplasmic proteins and 363 and 267 peaks from membrane proteins were extracted as specific peaks for cetuximab‑resistant and ‑sensitive CRC cell lines, respectively. By analyzing the proteins identified from the peptide peaks, cytoplasmic L‑lactate dehydrogenase B (LDHB) was detected as a marker of cetuximab sensitivity, and it was confirmed that LDHB expression was increased in cetuximab‑resistant CRC cell lines. Furthermore, LDHB expression levels were significantly upregulated with the acquisition of resistance to cetuximab in cetuximab‑sensitive CRC cell lines. In conclusion, LDHB was identified as an important factor affecting cetuximab sensitivity using comprehensive proteome analysis for the first time.Keywords
This publication has 52 references indexed in Scilit:
- Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panelProceedings of the National Academy of Sciences, 2012
- Lactate: A Metabolic Key Player in CancerCancer Research, 2011
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal CancerClinical Cancer Research, 2011
- Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy UsersCancer Research, 2010
- Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to TaxolMolecular Cancer, 2010
- Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer PatientsCancer Epidemiology, Biomarkers & Prevention, 2010
- Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progressionProceedings of the National Academy of Sciences, 2010
- Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cellsCell Stress and Chaperones, 2008
- Etoposide‐resistant HT‐29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down‐regulatorJournal of Cellular Physiology, 2007
- Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional StudyJNCI: Journal of the National Cancer Institute, 2007